Table of Content

Table of Contents

Global Drugs for Short Bowel Syndrome Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Drugs for Short Bowel Syndrome Market by Value
2.2.1 Global Drugs for Short Bowel Syndrome Revenue by Type
2.2.2 Global Drugs for Short Bowel Syndrome Market by Value (%)
2.3 Global Drugs for Short Bowel Syndrome Market by Production
2.3.1 Global Drugs for Short Bowel Syndrome Production by Type
2.3.2 Global Drugs for Short Bowel Syndrome Market by Production (%)

3. The Major Driver of Drugs for Short Bowel Syndrome Industry
3.1 Historical & Forecast Global Drugs for Short Bowel Syndrome Demand
3.2 Largest Application for Drugs for Short Bowel Syndrome (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Drugs for Short Bowel Syndrome Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Drugs for Short Bowel Syndrome Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Drugs for Short Bowel Syndrome Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Drugs for Short Bowel Syndrome Average Price Trend
12.1 Market Price for Each Type of Drugs for Short Bowel Syndrome in US (2018-2022)
12.2 Market Price for Each Type of Drugs for Short Bowel Syndrome in Europe (2018-2022)
12.3 Market Price for Each Type of Drugs for Short Bowel Syndrome in China (2018-2022)
12.4 Market Price for Each Type of Drugs for Short Bowel Syndrome in Japan (2018-2022)
12.5 Market Price for Each Type of Drugs for Short Bowel Syndrome in India (2018-2022)
12.6 Market Price for Each Type of Drugs for Short Bowel Syndrome in Korea (2018-2022)
12.7 Market Price for Each Type of Drugs for Short Bowel Syndrome in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Drugs for Short Bowel Syndrome Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Drugs for Short Bowel Syndrome

14. Drugs for Short Bowel Syndrome Competitive Landscape
14.1 Ardelyx
14.1.1 Ardelyx Company Profiles
14.1.2 Ardelyx Product Introduction
14.1.3 Ardelyx Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Emmaus Life Sciences
14.2.1 Emmaus Life Sciences Company Profiles
14.2.2 Emmaus Life Sciences Product Introduction
14.2.3 Emmaus Life Sciences Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 GLyPharma Therapeutic
14.3.1 GLyPharma Therapeutic Company Profiles
14.3.2 GLyPharma Therapeutic Product Introduction
14.3.3 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Merck
14.4.1 Merck Company Profiles
14.4.2 Merck Product Introduction
14.4.3 Merck Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Naia Pharmaceuticals
14.5.1 Naia Pharmaceuticals Company Profiles
14.5.2 Naia Pharmaceuticals Product Introduction
14.5.3 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Nutrinia
14.6.1 Nutrinia Company Profiles
14.6.2 Nutrinia Product Introduction
14.6.3 Nutrinia Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 OxThera
14.7.1 OxThera Company Profiles
14.7.2 OxThera Product Introduction
14.7.3 OxThera Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Sancilio & Company
14.8.1 Sancilio & Company Company Profiles
14.8.2 Sancilio & Company Product Introduction
14.8.3 Sancilio & Company Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Shire
14.9.1 Shire Company Profiles
14.9.2 Shire Product Introduction
14.9.3 Shire Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Zealand Pharma
14.10.1 Zealand Pharma Company Profiles
14.10.2 Zealand Pharma Product Introduction
14.10.3 Zealand Pharma Drugs for Short Bowel Syndrome Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Drugs for Short Bowel Syndrome Industry (Volume)
Figure 2. Drugs for Short Bowel Syndrome Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Drugs for Short Bowel Syndrome Revenue in 2022
Figure 5. US Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Drugs for Short Bowel Syndrome Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Drugs for Short Bowel Syndrome Revenue, by Type (Million USD) (2018-2028)
Table 4. Drugs for Short Bowel Syndrome Production, by Type (K Unit) (2018-2028)
Table 5. Drugs for Short Bowel Syndrome Demand (K Unit) by Application (2018-2028)
Table 6. Drugs for Short Bowel Syndrome Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Drugs for Short Bowel Syndrome Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Drugs for Short Bowel Syndrome Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Drugs for Short Bowel Syndrome in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Ardelyx Profiles
Table 61. Ardelyx Drugs for Short Bowel Syndrome Product Introduction
Table 62. Ardelyx Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Ardelyx Strategic initiatives
Table 64. Emmaus Life Sciences Profiles
Table 65. Emmaus Life Sciences Drugs for Short Bowel Syndrome Product Introduction
Table 66. Emmaus Life Sciences Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Emmaus Life Sciences Strategic initiatives
Table 68. GLyPharma Therapeutic Profiles
Table 69. GLyPharma Therapeutic Drugs for Short Bowel Syndrome Product Introduction
Table 70. GLyPharma Therapeutic Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. GLyPharma Therapeutic Strategic initiatives
Table 72. Merck Profiles
Table 73. Merck Drugs for Short Bowel Syndrome Product Introduction
Table 74. Merck Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Merck Strategic initiatives
Table 76. Naia Pharmaceuticals Profiles
Table 77. Naia Pharmaceuticals Drugs for Short Bowel Syndrome Product Introduction
Table 78. Naia Pharmaceuticals Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Naia Pharmaceuticals Strategic initiatives
Table 80. Nutrinia Profiles
Table 81. Nutrinia Drugs for Short Bowel Syndrome Product Introduction
Table 82. Nutrinia Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Nutrinia Strategic initiatives
Table 84. OxThera Profiles
Table 85. OxThera Drugs for Short Bowel Syndrome Product Introduction
Table 86. OxThera Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. OxThera Strategic initiatives
Table 88. Sancilio & Company Profiles
Table 89. Sancilio & Company Drugs for Short Bowel Syndrome Product Introduction
Table 90. Sancilio & Company Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Sancilio & Company Strategic initiatives
Table 92. Shire Profiles
Table 93. Shire Drugs for Short Bowel Syndrome Product Introduction
Table 94. Shire Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Shire Strategic initiatives
Table 97. Zealand Pharma Profiles
Table 98. Zealand Pharma Drugs for Short Bowel Syndrome Product Introduction
Table 99. Zealand Pharma Drugs for Short Bowel Syndrome Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Zealand Pharma Strategic initiatives